Nurix Therapeutics Inc (NASDAQ:NRIX) shares, rose in value on Wednesday, June 18, with the stock price up by 2.02% to the previous day’s close as strong demand from buyers drove the stock to $11.62.
Actively observing the price movement in the last trading, the stock closed the session at $11.39, falling within a range of $11.28 and $11.99. The value of beta (5-year monthly) was 2.156. Referring to stock’s 52-week performance, its high was $29.56, and the low was $8.18. On the whole, NRIX has fluctuated by 22.19% over the past month.
With the market capitalization of Nurix Therapeutics Inc currently standing at about $885.85 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-Apr-08.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that NRIX’s technical picture suggests that short-term indicators denote the stock is a Hold on average. However, medium-term indicators have put the stock in the category of 50% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of NRIX currently trading nearly 1.48% and 8.34% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 52.42, while the 7-day volatility ratio is showing 2.70% which for the 30-day chart, stands at 4.04%. Furthermore, Nurix Therapeutics Inc (NRIX)’s beta value is 2.16, and its average true range (ATR) is 0.69.
A comparison of Nurix Therapeutics Inc (NRIX) with its peers suggests the former has fared considerably weaker in the market. NRIX showed an intraday change of 2.02% in last session, and over the past year, it shrunk by -23.45%%.
Data on historical trading for Nurix Therapeutics Inc (NASDAQ:NRIX) indicates that the trading volumes over the past 10 days have averaged 0.71 and over the past 3 months, they’ve averaged 985.18K. According to company’s latest data on outstanding shares, there are 76.23 million shares outstanding.
Nearly 2.00% of Nurix Therapeutics Inc’s shares belong to company insiders and institutional investors own 110.63% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 14.09 million shares as on 2025-05-30, resulting in a short ratio of 18.91. According to the data, the short interest in Nurix Therapeutics Inc (NRIX) stood at 2172.00 of shares outstanding as of 2025-05-30; the number of short shares registered in 2025-04-30 reached 13.69 million. The stock has fallen by -38.32% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the NRIX stock heading into the next quarter.
